Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 6,7-dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine
- Correlated keywords
- inhibitors kinases inhibits inhibitions Src Lck I one Csk Yes blocks blocking blockers tyrosine VEGFR2 C-fms Cfms C fms serine/threonine serines threonines receptor-interacting protein-2 interacting 2 proteins RIP2 RIP-2 RIPs 2 two potent family non-receptor non receptors competitive
- Product Overview:
The Src kinases constitute a family of non-receptor tyrosine kinases, which includes Src and Lck. Src kinase inhibitor I is a potent competitive inhibitor of both Src and Lck (IC50 = 44 and 88 nM, respectively), as well as Csk and Yes.{23054,17331} It less effectively blocks the receptor tyrosine kinases VEGFR2 and C-fms (IC50 = 0.32 and 30 µM), as well as a long list of serine/threonine kinases.{23054,17331} Src Kinase Inhibitor I also inhibits receptor-interacting protein-2 with an IC50 value of 26 nM.{17331}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.